




The relative strengths and weaknesses of Sagent Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sagent Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Sagent Pharmaceuticals Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 287%, being 53% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	200,846
Cost of Goods Sold	0
Intangible Assets	5,426
Liabilities, Current	84,142
Liabilities, Non-Current	4,697
Other Assets	23,352
Other Compr. Net Income	877
Other Expenses	141,200
Other Liabilities	0
Other Net Income	284
Other Revenues	152,405
Property and Equipment	884
Research and Development	12,763
Selling, General and Administrative Expense	25,148

Output Variable	Value in 1000 USD
Assets	230,508
Liabilities	88,839
Expenses	179,111
Revenues	152,405
Stockholders Equity	141,669
Net Income	-26,422
Comprehensive Net Income	-25,984
BaseVar	326,012
ECR before LimitedLiability	177%
Economic Capital Ratio	287%